JP2015512949A5 - - Google Patents

Download PDF

Info

Publication number
JP2015512949A5
JP2015512949A5 JP2015505963A JP2015505963A JP2015512949A5 JP 2015512949 A5 JP2015512949 A5 JP 2015512949A5 JP 2015505963 A JP2015505963 A JP 2015505963A JP 2015505963 A JP2015505963 A JP 2015505963A JP 2015512949 A5 JP2015512949 A5 JP 2015512949A5
Authority
JP
Japan
Prior art keywords
cyclodextrin
composition
diabetes
cholesterol
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015505963A
Other languages
English (en)
Japanese (ja)
Other versions
JP6491089B2 (ja
JP2015512949A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/036484 external-priority patent/WO2013155485A2/en
Publication of JP2015512949A publication Critical patent/JP2015512949A/ja
Publication of JP2015512949A5 publication Critical patent/JP2015512949A5/ja
Application granted granted Critical
Publication of JP6491089B2 publication Critical patent/JP6491089B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015505963A 2012-04-13 2013-04-12 シクロデキストリンを使用するための方法 Active JP6491089B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261624087P 2012-04-13 2012-04-13
US61/624,087 2012-04-13
PCT/US2013/036484 WO2013155485A2 (en) 2012-04-13 2013-04-12 Method of using cyclodextrin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018150978A Division JP2018203747A (ja) 2012-04-13 2018-08-10 シクロデキストリンを使用するための方法

Publications (3)

Publication Number Publication Date
JP2015512949A JP2015512949A (ja) 2015-04-30
JP2015512949A5 true JP2015512949A5 (enExample) 2016-06-09
JP6491089B2 JP6491089B2 (ja) 2019-03-27

Family

ID=49328287

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015505963A Active JP6491089B2 (ja) 2012-04-13 2013-04-12 シクロデキストリンを使用するための方法
JP2018150978A Pending JP2018203747A (ja) 2012-04-13 2018-08-10 シクロデキストリンを使用するための方法
JP2021103893A Pending JP2021155436A (ja) 2012-04-13 2021-06-23 シクロデキストリンを使用するための方法
JP2023146755A Pending JP2023178518A (ja) 2012-04-13 2023-09-11 シクロデキストリンを使用するための方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2018150978A Pending JP2018203747A (ja) 2012-04-13 2018-08-10 シクロデキストリンを使用するための方法
JP2021103893A Pending JP2021155436A (ja) 2012-04-13 2021-06-23 シクロデキストリンを使用するための方法
JP2023146755A Pending JP2023178518A (ja) 2012-04-13 2023-09-11 シクロデキストリンを使用するための方法

Country Status (8)

Country Link
US (4) US10195227B2 (enExample)
EP (2) EP4299121A3 (enExample)
JP (4) JP6491089B2 (enExample)
CN (2) CN111419870A (enExample)
CA (1) CA2870316C (enExample)
ES (1) ES2959119T3 (enExample)
MX (2) MX392972B (enExample)
WO (1) WO2013155485A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX392972B (es) * 2012-04-13 2025-03-21 L&F Res Llc Metodo para utilizar ciclodextrina.
EP2968083B1 (en) 2013-03-12 2021-09-22 Primal Therapies, Inc. Dental composition comprising chelator and base
JP6418911B2 (ja) * 2014-11-18 2018-11-07 学校法人中部大学 Ｇｌｐ−１分泌促進剤
CA2988529A1 (en) 2015-06-10 2016-12-15 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
CN105395549A (zh) * 2015-11-03 2016-03-16 天津医科大学总医院 烟酸的新用途
EP3515501A1 (en) * 2016-09-19 2019-07-31 Aten Porus Lifesciences Cyclodextrin based polymers, methods, compositions and applications thereof
WO2018075622A1 (en) * 2016-10-19 2018-04-26 University Of Miami Materials and methods for modulating insulin signaling and preserving podocyte function
CN107982546A (zh) * 2017-12-05 2018-05-04 中国药科大学 基于主客体相互作用的酸敏感超分子纳米粒及其应用
US11925659B2 (en) 2018-10-29 2024-03-12 Cyclo Therapeutics, Inc. Methods for treating Alzheimer's disease
AU2020204925B2 (en) 2019-01-03 2025-11-20 Cyclarity Therapeutics, Inc. Cyclodextrin dimers, compositions thereof, and uses thereof
PH12021552553A1 (en) * 2019-04-16 2022-06-20 Celagenex Res India Pvt Ltd Synergistic lipid controlling compositions
KR20220098009A (ko) * 2019-11-11 2022-07-08 아츠오 오치 체세포를 재프로그래밍하기 위한 방법 및 키트
US12226431B2 (en) 2021-09-11 2025-02-18 Porosome Therapeutics, Inc. Aerosol and topical administration of a formulation containing cyclodextrin, quercetin and zinc, in combination or separately, to mitigate infection by enveloped viruses
PE20231169A1 (es) * 2020-08-27 2023-07-26 Beren Therapeutics P B C Metodos para el tratamiento de enfermedades cardiovasculares con ciclodextrinas
WO2022047241A1 (en) * 2020-08-27 2022-03-03 Beren Therapeutics P.B.C. Methods for the treatment of cholesterol crystal embolization with cyclodextrins
EP4203973A4 (en) * 2020-08-27 2024-08-21 Beren Therapeutics P.B.C. METHOD FOR PREVENTING CHOLESTEROL CRYSTAL EMBOLISATION WITH CYCLODEXTRINS
CN112089843B (zh) * 2020-10-13 2022-11-04 合肥工业大学 一种抗心力衰竭的联用组合药物及其在制备抗心力衰竭药物中的应用
WO2022178318A1 (en) * 2021-02-18 2022-08-25 Beren Therapeutics P.B.C. Methods for the treatment of familial heterozygous and homozygous hypercholesterolemia with cyclodextrins
CN113295793B (zh) * 2021-05-20 2022-11-04 复旦大学附属中山医院 预测早期糖尿病以及糖尿病发生的生物标志物、其检测方法与应用
EP4198061A4 (en) * 2021-09-01 2024-10-23 Renatus Inc. PHARMACEUTICAL COMPOSITION COMPRISING A GAMMA-CYCLODEXTRIN POLYMER AND ITS USE
KR20240160120A (ko) 2022-02-18 2024-11-08 베렌 테라퓨틱스 피.비.씨. 하이드록시프로필-베타-사이클로덱스트린의 조성물 및 이의 정제 방법

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0672100B2 (ja) * 1989-11-15 1994-09-14 株式会社上野製薬応用研究所 利尿剤
US5840713A (en) * 1995-04-03 1998-11-24 Weisz; Paul B. Therapy for tissue membrane insufficiency
EP1125584A4 (en) 1998-10-30 2005-01-12 Takeda Chemical Industries Ltd PREPARATIONS CONTAINING BETACELLULIN PROTEIN
US6756504B2 (en) * 2000-04-19 2004-06-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Sphingolipids
US20040121983A1 (en) * 2002-08-12 2004-06-24 Council Of Scientific And Industrial Research Method for treating leishmaniasis using methyl-beta-cyclodextrin
JP4418751B2 (ja) 2002-08-19 2010-02-24 アート・ジェン・コンプレクサス・インコーポレイテッド 食物脂肪複合化剤を含む組成物およびそれらの利用法
JP2004323443A (ja) * 2003-04-25 2004-11-18 Tokai Univ 抗血栓薬
EP1635813A4 (en) * 2003-06-06 2009-07-01 Merck & Co Inc COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA
US9200245B2 (en) 2003-06-26 2015-12-01 Seng Enterprises Ltd. Multiwell plate
US7393826B2 (en) * 2003-07-03 2008-07-01 Lipid Sciences, Inc. Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
US7276351B2 (en) 2003-09-10 2007-10-02 Seahorse Bioscience Method and device for measuring multiple physiological properties of cells
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
CN1282425C (zh) * 2004-06-22 2006-11-01 王美岭 苹果醋营养品及其生产方法
US20060128653A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of decitabine
JP2006191830A (ja) * 2005-01-12 2006-07-27 Unitika Ltd 脂肪の蓄積を抑制する食品
AU2006208109A1 (en) 2005-01-27 2006-08-03 Erimos Pharmaceuticals Llc Formulations for injection of catecholic butanes, including NDGA compounds, into animals
US7670817B2 (en) 2005-11-08 2010-03-02 The General Hospital Corporation Dynamin mediated diseases and associated methods and products
US20090324624A1 (en) * 2006-06-16 2009-12-31 Florida Atlantic University Chitin micro-particles as an adjuvant
EP1894924A1 (en) * 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
AU2007325576B2 (en) * 2006-10-20 2013-01-10 Icos Corporation Compositions of Chk1 inhibitors
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
WO2010042202A1 (en) 2008-10-07 2010-04-15 Fibrogen, Inc. Methods for treatment of podocyte injury
US20100189653A1 (en) * 2008-10-10 2010-07-29 Wendye Robbins Pyrone analogs for therapeutic treatment
US8202702B2 (en) 2008-10-14 2012-06-19 Seahorse Bioscience Method and device for measuring extracellular acidification and oxygen consumption rate with higher precision
US8263413B1 (en) 2008-10-17 2012-09-11 Andrew S Hansen Methods for analyzing lipids and membrane proteins in biological matter using stable isotopes and mass spectrometry
WO2010054167A2 (en) 2008-11-06 2010-05-14 University Of Miami Limited proteolysis of cd2ap and progression of renal disease
US20110314423A1 (en) 2009-03-12 2011-12-22 Panasonic Corporation Image display device and image display method
US8975241B2 (en) * 2009-10-08 2015-03-10 Song Ho Biomed Co., Ltd. Composition for treating and preventing obesity including high water-soluble 2-hydroxypropyl-betacyclodextrin as effective component
US20120251527A1 (en) 2009-11-06 2012-10-04 University Of Miami Podocyte specific assays and uses thereof
US8372877B2 (en) * 2010-04-16 2013-02-12 Cumberland Pharmaceuticals Stabilized statin formulations
EP2595623B1 (en) * 2010-07-19 2018-02-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Use of delta tocopherol for the treatment of lysosomal storage disorders
CA2930119C (en) 2010-10-19 2019-10-29 University Of Miami Assays, methods and kits for predicting renal disease and personalized treatment strategies
MX392972B (es) * 2012-04-13 2025-03-21 L&F Res Llc Metodo para utilizar ciclodextrina.

Similar Documents

Publication Publication Date Title
JP2015512949A5 (enExample)
Jeong Nonalcoholic fatty liver disease: a drug revolution is coming
CN103717219B (zh) 左心室舒张功能改善剂
US20240358718A1 (en) Concomitant administration of glucocorticoid receptor modulators and cyp3a inhibitors
JP5302900B2 (ja) 脂肪性肝疾患の治療用医薬組成物
JP2011512347A5 (enExample)
CN110022877B (zh) 用于治疗非酒精性脂肪性肝病的5-[[4-[2-[5-(1-羟基乙基)吡啶-2-基]乙氧基]苯基]甲基]-1,3-噻唑烷-2,4-二酮
Parfianowicz et al. Finerenone: a new era for mineralocorticoid receptor antagonism and cardiorenal protection
ES2525748T3 (es) Agente terapéutico o profiláctico para la diabetes
Chong et al. Emerging drugs for the treatment of angina pectoris
Li et al. GLP-1R in diabetes mellitus: from basic discovery to therapeutics development
CA3137138A1 (en) Methods of treating hypertension with activators of tie-2
US20220265776A1 (en) Combination
WO2014036603A1 (en) Uses of (-)-perhexiline
WO2023026247A1 (en) Combination of a nurr1 agonist with at least one of an aldosterone antagonist, an insulin modulator and a sulfonylurea
Tan et al. Therapeutic Potential of Metformin in Diabetes Mellitus-Related Cardiovascular Complications
EP4527385A1 (en) Il-6 and/or il-1? inhibitor
JP4433496B2 (ja) Ａｔｐクエン酸リアーゼの発現抑制用医薬組成物及びその使用
Pleasants Medication safety in chronic lung disease with cardiac comorbidity
WO2011121182A1 (en) Pharmaceutical composition comprising gemfibrozil and cyp2c8 and/or oatp substrate drug such as repaglinide
JPH11189537A (ja) プロスタグランジン類の医薬用途
HK40063597A (en) Methods of treating hypertension with activators of tie-2
JP2010520854A (ja) 高コレステロール血症の治療又は予防において使用するためのニトロキシド
Tarkin et al. Pharmacological Profile of Nicorandil
Potpara et al. Novel Oral Anticoagulants for Thromboprophylaxis in Non-Valvular Atrial Fibrillation: Focus on Randomized Clinical Trials